Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature Precedings
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • RSS feed
  1. nature
  2. nature precedings
  3. articles
  4. article
Characteristics of Uremic Cardiomyopathy with Reversible Systolic Dysfunction
Download PDF
Download PDF
  • Manuscript
  • Open access
  • Published: 14 May 2009

Characteristics of Uremic Cardiomyopathy with Reversible Systolic Dysfunction

  • Srilakshmi Adhyapak1 &
  • Shamanna Iyengar1 

Nature Precedings (2009)Cite this article

  • 391 Accesses

  • Metrics details

Abstract

Background:

There exists a sub group of patients with uremic cardiomyopathy who experience resolution of heart failure following hemodialysis. It has been hypothesized that these patients are fluid overloaded, and following hemodialysis, show improvements in cardiac geometry and function. We wanted to study their clinical, biochemical and echocardiographic features to define any other additional characteristics.Aim: To define characteristics of reversible systolic dysfunction.Methods: We studied 72 patients with chronic kidney disease on hemodialysis of whom 52 presented with congestive heart failure, over a period of 190 days. We studied their echocardiographic profile and blood biochemistry parameters including troponin I and C reactive protein.

Results:

There were 29 patients with systolic dysfunction (LVEF≤40%). Twenty three patients with preserved systolic function, had diastolic dysfunction. Of the 29 patients with systolic dysfunction, 10 patients had significant improvement in NYHA functional class, and left ventricular dimensions (LVIDd:59.8±2.6 mm to 55.9±2 mm and LVIDs:51.8±1.8 mm to 34±1.2 mm; p<0.001) with significant increase in left ventricular ejection fraction (30.5±5% to 50.1±4%; p<0.001). These patients had the highest serum levels of troponin I (p=0.024) which decreased significantly with recovery of cardiac function. In the patients with persistent systolic dysfunction and in the patients with diastolic function, the troponin I remained high. The troponin I was significantly lesser in the control group (p=0.002).

Conclusions:

A sub group of patients with uremic cardiomyopathy demonstrated reversible left ventricular systolic dysfunction, and high levels of serum troponin I levels at presentation, which regressed with recovery of ventricular function.

Similar content being viewed by others

Prognostic impacts of left ventricular strain in hemodialytic patients with preserved left ventricular systolic function

Article Open access 09 July 2025

Understanding and recognition of the right ventricular function and dysfunction via a numerical study

Article Open access 12 February 2021

The moderating effect of fluid overload on the relationship between the augmentation index and left ventricular diastolic function in patients with CKD

Article Open access 04 January 2024

Article PDF

Author information

Authors and Affiliations

  1. Department Of Cardiology, St.John’s Medical College Hospital, India

    Srilakshmi Adhyapak & Shamanna Iyengar

Authors
  1. Srilakshmi Adhyapak
    View author publications

    Search author on:PubMed Google Scholar

  2. Shamanna Iyengar
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Creative Commons Attribution 3.0 License.

Reprints and permissions

About this article

Cite this article

Adhyapak, S., Iyengar, S. Characteristics of Uremic Cardiomyopathy with Reversible Systolic Dysfunction. Nat Prec (2009). https://doi.org/10.1038/npre.2009.3199.1

Download citation

  • Received: 29 April 2009

  • Accepted: 14 May 2009

  • Published: 14 May 2009

  • DOI: https://doi.org/10.1038/npre.2009.3199.1

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • uremic cardiomyopathy
  • troponin I
  • ventricular disfunction
  • Heart
Download PDF

Advertisement

Explore content

  • Research articles
  • News & Comment
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Nature Precedings (Nat Preced)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing